ReviewPharmaceutics2023
DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 42 citations in OpenAlex.
- 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Deciphering the phenotypic responses toEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Structural and Functional Characteristics of the Liver After Fractionated Local Electron Irradiation and Against the Background of Ascorbic Acid Administration.Journal of personalized medicine · 2026Review
- Stable core-encapsulation of indium-111 in crosslinked polyionic complex micelles and assessment of its biodistribution.EJNMMI radiopharmacy and chemistry · 2026Article
- A Spatiotemporal Image-Guided Model of Radiopharmaceutical Transport in Heterogeneous Vasculature Prostate Tumor: A Computational Analysis of Key Parameters in Lutetium-177 PSMA Therapy.Annals of biomedical engineering · 2026Article
- B7-H4-targeted radiotheranostics enable precise imaging and potent therapy across solid tumor models.Science advances · 2026Article
- Clinical and research applications of fibroblast activation protein-α inhibitor tracers: a review.The British journal of radiology · 2026Review
- [European journal of nuclear medicine and molecular imaging · 2026Article
- Personalised Dosimetry in Nuclear Medicine: Bridging Physics, Biology and AI for Next Generation Radiopharmaceutical Therapy.Nuclear medicine and molecular imaging · 2026Review
- Radiation Biology of Radiopharmaceuticals: Beyond External Beam Radiation Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- In Vivo Studies of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Medical Management of Well-Differentiated Pancreatic Neuroendocrine Tumors: From Conventional Therapies to Emerging Strategies.Journal of clinical medicine · 2026Review
- Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026Review
- Modern brachytherapy in glioblastoma: overcoming clinical barriers to improve local control.Frontiers in oncology · 2026Review
- Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates.Frontiers in oncology · 2026Review
- Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [Scientific reports · 2025Article
- Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace.International journal of radiation oncology, biology, physics · 2025Article
- Quantifying DNA strand breaks from targeted alpha emittersEJNMMI physics · 2025Article
- WGX50 attenuates radiation enteritis by targeting ferroptosis and redox homeostasis via EGFR.Molecular medicine (Cambridge, Mass.) · 2025Article
- Poly(ADP-ribose) polymerase-1 in breast cancers: expression level and its association in various molecular subtypes with a focus in Africa.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
DNA is an organic molecule that is highly vulnerable to chemical alterations and breaks caused by both internal and external factors. Cells possess complex and advanced mechanisms, including DNA repair, damage tolerance, cell cycle checkpoints, and cell death pathways, which together minimize the potentially harmful effects of DNA damage. However, in cancer cells, the normal DNA damage tolerance and response processes are disrupted or deregulated. This results in increased mutagenesis and genomic instability within the cancer cells, a known driver of cancer progression and therapeutic resistance. On the other hand, the inherent instability of the genome in rapidly dividing cancer cells can be exploited as a tool to kill by imposing DNA damage with radiopharmaceuticals. As the field of targeted radiopharmaceutical therapy (RPT) is rapidly growing in oncology, it is crucial to have a deep understanding of the impact of systemic radiation delivery by radiopharmaceuticals on the DNA of tumors and healthy tissues. The distribution and activation of DNA damage and repair pathways caused by RPT can be different based on the characteristics of the radioisotope and molecular target. Here we provide a comprehensive discussion of the biological effects of RPTs, with the main focus on the role of varying radioisotopes in inducing direct and indirect DNA damage and activating DNA repair pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.